Cover Image
市場調查報告書

麻醉效果:開發中產品分析

Anesthetic Effect - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253649
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
麻醉效果:開發中產品分析 Anesthetic Effect - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 90 Pages
簡介

麻醉效果,是增加意識喪失的併發症風險的主要要素,還有抽煙和閉塞型睡眠呼吸中止症,肥胖,高血壓,麻醉的副作用的病歷,對醫藥品的過敏體質等。

本報告提供全球各國的麻醉效果治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及臨床實驗各階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

麻醉效果概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

麻醉效果:企業開發中的治療藥

麻醉效果:大學/機關研究中的治療藥

麻醉效果:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

麻醉效果:企業開發中的產品

麻醉效果:大學/機關研究中的產品

麻醉效果治療藥的開發企業

  • Advicenne Pharma
  • Biolab Sanus Farmaceutica Ltda.
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Juniper Pharmaceuticals, Inc.
  • Laboratoires Thea S.A.
  • Lipicard Technologies Limited
  • Merck & Co., Inc.
  • NanoMedex Pharmaceuticals, Inc.
  • Paion AG
  • Phosphagenics Limited
  • Physica Pharma SAS
  • Proteus SA
  • Sphaera Pharma Pvt. Ltd.
  • Taiwan Liposome Company, Ltd.
  • The Medicines Company

麻醉效果:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

麻醉效果:最近的開發平台趨勢

麻醉效果:暫停中的計劃

麻醉效果:開發中止的產品

麻醉效果:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8497IDB

Summary

Global Markets Direct's, 'Anesthetic Effect - Pipeline Review, H2 2016', provides an overview of the Anesthetic Effect pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
  • The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects
  • The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anesthetic Effect

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anesthetic Effect Overview
  • Therapeutics Development
    • Pipeline Products for Anesthetic Effect - Overview
    • Pipeline Products for Anesthetic Effect - Comparative Analysis
  • Anesthetic Effect - Therapeutics under Development by Companies
  • Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes
  • Anesthetic Effect - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Anesthetic Effect - Products under Development by Companies
  • Anesthetic Effect - Products under Investigation by Universities/Institutes
  • Anesthetic Effect - Companies Involved in Therapeutics Development
    • Biolab Farmaceutica Ltda
    • Drawbridge Pharmaceuticals Pty Ltd
    • Expanesthetics Inc
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Lipicard Technologies Limited
    • NanoMedex Pharmaceuticals, Inc.
    • Paion AG
    • Phosphagenics Limited
    • Physica Pharma
    • Primex Pharmaceuticals Oy
    • Proteus SA
    • Sphaera Pharma Pvt. Ltd.
    • Taiwan Liposome Company, Ltd.
    • The Medicines Company
  • Anesthetic Effect - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABP-700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADV-6209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alphaxalone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bupivacaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Carboetomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gabafol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSK-3486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Methoxycarbonyl Carboetomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Methoxycarbonyl Etomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neosaxitoxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-5109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHY-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol microemulsion - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for General Anesthetic Effect - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for General Anesthetic Effect - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPR-819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anesthetic Effect - Dormant Projects
  • Anesthetic Effect - Discontinued Products
  • Anesthetic Effect - Product Development Milestones
    • Featured News & Press Releases
      • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
      • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
      • Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
      • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
      • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
      • Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings
      • Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting
      • Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015
      • Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
      • Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
      • Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
      • Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion
      • Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
      • Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014
      • Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anesthetic Effect, H2 2016
  • Number of Products under Development for Anesthetic Effect - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2016
  • Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2016
  • Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2016
  • Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H2 2016
  • Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2016
  • Anesthetic Effect - Pipeline by Paion AG, H2 2016
  • Anesthetic Effect - Pipeline by Phosphagenics Limited, H2 2016
  • Anesthetic Effect - Pipeline by Physica Pharma, H2 2016
  • Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H2 2016
  • Anesthetic Effect - Pipeline by Proteus SA, H2 2016
  • Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016
  • Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Anesthetic Effect - Pipeline by The Medicines Company, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Anesthetic Effect - Dormant Projects, H2 2016
  • Anesthetic Effect - Dormant Projects (Contd..1), H2 2016
  • Anesthetic Effect - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Anesthetic Effect, H2 2016
  • Number of Products under Development for Anesthetic Effect - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top